Palazestrant + Fulvestrant + Anastrozole + Letrozole + Exemestane
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Trial Timeline
Nov 16, 2023 → Sep 30, 2027
NCT ID
NCT06016738About Palazestrant + Fulvestrant + Anastrozole + Letrozole + Exemestane
Palazestrant + Fulvestrant + Anastrozole + Letrozole + Exemestane is a phase 3 stage product being developed by Olema Pharmaceuticals for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06016738. Target conditions include Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06016738 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Cancer